Type 1 diabetes mellitus: the liver’s role, sex-specific outcomes, and advances in disease-modifying therapies - a literature review

Abstract

Type 1 Diabetes Mellitus (T1DM) is a chronic autoimmune disease characterized by the destruction of pancreatic β-cells, leading to insulin deficiency. While insulin remains the cornerstone of treatment, achieving optimal disease control and preventing long-term complications remain significant challenges. This review synthesizes recent findings on the epidemiology, pathophysiology, and management of T1DM, with a particular focus on sex-based differences in disease presentation and outcomes, the role of the liver, and the emerging significance of C-peptide in understanding disease complications. Additionally, the involvement of T cells and B cells in the immune response and the potential of disease-modifying therapies, such as TNF-alpha inhibitors, anti-CD3 antibodies, abatacept, and cell-based therapies, are explored. The article highlights the need for further research into personalized and gender-specific treatment approaches and the development of novel therapeutic strategies. Addressing these critical areas may lead to improved disease management and quality of life for individuals with T1DM, paving the way for more effective and individualized therapeutic interventions.

Keywords

Type 1 diabetes mellitus / diabetic kidney disease / diabetic nephropathy / hyperglycemia / C-peptide / lymphocytes / therapies / treatments

References

[1] Mauvais-Jarvis F.Gender differences in glucose homeostasis and diabetes.Physiol Behav2018;187:20-3 PMCID:PMC5826763

[2] Memaj P.Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology.Front Endocrinol2022;13:1031633 PMCID:PMC9752856

[3] Vries M, Westerink J, Kaasjager KHAH, de Valk HW. Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis.J Clin Endocrinol Metab2020;105:3842-53 PMCID:PMC7526735

[4] Shi Y,Sun Y.The prevalence of lean/nonobese nonalcoholic fatty liver disease: a systematic review and meta-analysis.J Clin Gastroenterol2020;54:378-87

[5] Ryk A,Michalak A.Biological activity of c-peptide in microvascular complications of type 1 diabetes-time for translational studies or back to the basics?.Int J Mol Sci2020;21:9723 PMCID:PMC7766542

[6] Wahren J.C-peptide: new findings and therapeutic possibilities.Diabetes Res Clin Pract2015;107:309-19

[7] Mastrandrea L,Behrens T.Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study.Diabetes Care2009;32:1244-9

[8] Quattrin T,Steck AK.T1GER Study InvestigatorsGolimumab and beta-cell function in youth with new-onset type 1 diabetes.N Engl J Med2020;383:2007-17

[9] Herold KC,Perdigoto AL,Brusko TM.The immunology of type 1 diabetes.Nat Rev Immunol2024;24:435-51 PMCID:PMC7616056

[10] Bazile C,Ackeifi C.TNF-α inhibitors for type 1 diabetes: exploring the path to a pivotal clinical trial.Front Immunol2024;15:1470677 PMCID:PMC11473295

[11] Vries SAG, Verheugt CL, Mul D, Nieuwdorp M, Sas TCJ. Do sex differences in paediatric type 1 diabetes care exist?.Diabetologia2023;66:618-30 PMCID:PMC9947056

[12] Maahs DM,Lawrence JM.Epidemiology of type 1 diabetes.Endocrinol Metab Clin North Am2010;39:481-97 PMCID:PMC2925303

[13] Agarwal S,Raymond JK.Racial-ethnic inequity in young adults with type 1 diabetes.J Clin Endocrinol Metab2020;105:e2960-9 PMCID:PMC7457963

[14] Shepard BD.Sex differences in diabetes and kidney disease: mechanisms and consequences.Am J Physiol Renal Physiol2019;317:F456-62 PMCID:PMC6732459

[15] Giandalia A,Gembillo G.Gender differences in diabetic kidney disease: focus on hormonal, genetic and clinical factors.Int J Mol Sci2021;22:5808 PMCID:PMC8198374

[16] Ohkuma T,Peters SAE.Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals.Diabetologia2019;62:1550-60 PMCID:PMC6677875

[17] Chase-Vilchez AZ,Peters SAE.Diabetes as a risk factor for incident peripheral arterial disease in women compared to men: a systematic review and meta-analysis.Cardiovasc Diabetol2020;19:151 PMCID:PMC7520021

[18] Peters SA,Woodward M.Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events.Diabetologia2014;57:1542-51

[19] Wang Y,Jiao Y.Sex differences in the association between diabetes and risk of cardiovascular disease, cancer, and all-cause and cause-specific mortality: a systematic review and meta-analysis of 5,162,654 participants.BMC Med2019;17:136 PMCID:PMC6625042

[20] Wei G,Shen FJ.Heterogeneous metabolic changes of brown and white adipose tissues are associated with metabolic adaptations in periparturient mice.J Mol Endocrinol2024;73:e240012

[21] Frias JP,Ofrecio J,Olefsky JM.Decreased susceptibility to fatty acid-induced peripheral tissue insulin resistance in women.Diabetes2001;50:1344-50

[22] Nuutila P,Mäki M.Gender and insulin sensitivity in the heart and in skeletal muscles: studies using positron emission tomography.Diabetes1995;44:31-6

[23] Brener A,Interator H.Sex differences in body composition in youth with type 1 diabetes and its predictive value in cardiovascular disease risk assessment.Diabetes Metab Res Rev2023;39:e3584 PMCID:PMC10078230

[24] Schweiger D, Battelino T, Groselj U. Sex-related differences in cardiovascular disease risk profile in children and adolescents with type 1 diabetes.Int J Mol Sci2021;22:10192 PMCID:PMC8508122

[25] Braffett BH,El Ghormli L.DCCT/EDIC Research GroupCardiometabolic risk factors and incident cardiovascular disease events in women vs men with type 1 diabetes.JAMA Netw Open2022;5:e2230710 PMCID:PMC9459657

[26] Nyström L,Ostman J.Risk of developing insulin-dependent diabetes mellitus (IDDM) before 35 years of age: indications of climatological determinants for age at onset.Int J Epidemiol1992;21:352-8

[27] Blohmé G,Arnqvist HJ.Male predominance of type 1 (insulin-dependent) diabetes mellitus in young adults: results from a 5-year prospective nationwide study of the 15-34-year age group in Sweden.Diabetologia1992;35:56-62

[28] Laing SP,Slater SD.Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes.Diabetologia2003;46:760-5

[29] Harjutsalo V,Forsblom C.Impact of sex and age at onset of diabetes on mortality from ischemic heart disease in patients with type 1 diabetes.Diabetes Care2014;37:144-8

[30] Bisson A,Fauchier G.Sex, age, type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a nationwide analysis.Cardiovasc Diabetol2021;20:24 PMCID:PMC7821402

[31] Tas E,Mendizabal B,Muzumdar R.Relationship between liver and cardiometabolic health in type 1 diabetes.Front Endocrinol2024;15:1505430 PMCID:PMC11598439

[32] Rakusanova S.Metabolomics and lipidomics for studying metabolic syndrome: insights into cardiovascular diseases, type 1 & 2 diabetes, and metabolic dysfunction-associated steatotic liver disease.Physiol Res2024;73:S165-83 PMCID:PMC11412346

[33] Boulos M,Jeries N.Hidden in the fat: unpacking the metabolic tango between metabolic dysfunction-associated steatotic liver disease and metabolic syndrome.Int J Mol Sci2025;26:3448 PMCID:PMC11989262

[34] Bourganou MV,Kyrou I.Unraveling metabolic dysfunction-associated steatotic liver disease through the use of omics technologies.Int J Mol Sci2025;26:1589 PMCID:PMC11855544

[35] Wang JS,Lin KD,Hsu YH.Diabetes Kidney Disease Research Committee of the Diabetes Association of the Republic of China (Taiwan)Epidemiological characteristics of diabetic kidney disease in Taiwan.J Diabetes Investig2021;12:2112-23 PMCID:PMC8668071

[36] Lord S.Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes.F1000Res2020;9:827 PMCID:PMC7400689

[37] Regnell SE.Hepatic steatosis in type 1 diabetes.Rev Diabet Stud2011;8:454-67 PMCID:PMC3359690

[38] Im SS,Kim SY.Glucose-stimulated upregulation of GLUT2 gene is mediated by sterol response element-binding protein-1c in the hepatocytes.Diabetes2005;54:1684-91

[39] Thorens B,Lodish HF.Differential regulation of two glucose transporters in rat liver by fasting and refeeding and by diabetes and insulin treatment.Diabetes1990;39:712-9

[40] Gastaldelli A.From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options.JHEP Rep2019;1:312-28 PMCID:PMC7001557

[41] Manco M.Insulin resistance and NAFLD: a dangerous liaison beyond the genetics.Children2017;4:74 PMCID:PMC5575596

[42] Petta S,Rebelos E.Pathophysiology of non alcoholic fatty liver disease.Int J Mol Sci2016;17:2082 PMCID:PMC5187882

[43] Mertens J,Spinhoven M,Francque SM.Hepatopathy associated with type 1 diabetes: distinguishing non-alcoholic fatty liver disease from glycogenic hepatopathy.Front Pharmacol2021;12:768576 PMCID:PMC8573337

[44] Mohamed J,Zariyantey AH.Mechanisms of diabetes-induced liver damage: the role of oxidative stress and inflammation.Sultan Qaboos Univ Med J2016;16:e132-41 PMCID:PMC4868511

[45] Rafaqat S,Khalid A.Role of liver parameters in diabetes mellitus - a narrative review.Endocr Regul2023;57:200-20

[46] West J,Gazis A.Elevated serum alanine transaminase in patients with type 1 or type 2 diabetes mellitus.QJM2006;99:871-6

[47] Huo G.Type 1 diabetes and combined acute and chronic complications are associated with risk of progression of liver fibrosis: a Mendelian randomization study.Front Endocrinol2024;15:1302611 PMCID:PMC11330757

[48] Rawshani A,Franzén S.Mortality and cardiovascular disease in type 1 and type 2 diabetes.N Engl J Med2017;376:1407-18

[49] Donaghue K.Traditional cardiovascular risk factors in adolescents with type 1 diabetes mellitus.Curr Diabetes Rev2017;13:533-43

[50] Della Pepa G,Masulli M.Blood glucose control and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes.J Endocrinol Invest2024;47:2371-8 PMCID:PMC11368973

[51] Caldara R,Monti P.Allo beta cell transplantation: specific features, unanswered questions, and immunological challenge.Front Immunol2023;14:1323439 PMCID:PMC10701551

[52] Zhou A,Zhu X.Proteolytic processing in the secretory pathway.J Biol Chem1999;274:20745-8

[53] Chima RS,Lamontagne T.C-peptide ameliorates kidney injury following hemorrhagic shock.Shock2011;35:524-9

[54] Luppi P,Tse H,Trucco M.Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-κB pathway.Diabetologia2008;51:1534-43

[55] Krishna SV, Kota SK, Modi KD. Glycemic variability: clinical implications.Indian J Endocrinol Metab2013;17:611-9 PMCID:PMC3743360

[56] Ido Y,Chang K.Prevention of vascular and neural dysfunction in diabetic rats by C-peptide.Science1997;277:563-6

[57] Sima AA,Sugimoto K.C-peptide prevents and improves chronic Type I diabetic polyneuropathy in the BB/Wor rat.Diabetologia2001;44:889-97

[58] Redondo MJ,Steck AK.Type 1 Diabetes TrialNet Study GroupA type 1 diabetes genetic risk score predicts progression of islet autoimmunity and development of type 1 diabetes in individuals at risk.Diabetes Care2018;41:1887-94

[59] Redondo MJ,Libman I.Single islet autoantibody at diagnosis of clinical type 1 diabetes is associated with older age and insulin resistance.J Clin Endocrinol Metab2020;105:1629-40 PMCID:PMC7089846

[60] Leslie RD,Freund-Brown J.Adult-onset type 1 diabetes: current understanding and challenges.Diabetes Care2021;44:2449-56 PMCID:PMC8546280

[61] Jamiołkowska-Sztabkowska M,Bossowski A.C-peptide and residual β-cell function in pediatric diabetes - state of the art.Pediatr Endocrinol Diabetes Metab2021;27:123-33 PMCID:PMC10214969

[62] Wahren J.C-peptide and the pathophysiology of microvascular complications of diabetes.J Intern Med2017;281:3-6

[63] Luppi P,Wahren J.Can C-peptide mediated anti-inflammatory effects retard the development of microvascular complications of type 1 diabetes?.Diabetes Metab Res Rev2013;29:357-62

[64] Jones AG.The clinical utility of C-peptide measurement in the care of patients with diabetes.Diabet Med2013;30:803-17 PMCID:PMC3748788

[65] Wahren J,Sima AA.The clinical potential of C-peptide replacement in type 1 diabetes.Diabetes2012;61:761-72 PMCID:PMC3314360

[66] Washburn RL,Kaur G.C-peptide as a therapy for type 1 diabetes mellitus.Biomedicines2021;9:270 PMCID:PMC8000702

[67] Marques RG,Rogers J.C-peptide: much more than a byproduct of insulin biosynthesis.Pancreas2004;29:231-8

[68] Chen J,Liu C,Wang Y.The role of C-peptide in diabetes and its complications: an updated review.Front Endocrinol2023;14:1256093 PMCID:PMC10512826

[69] Alam S,Lee CYF,Murtaza SF.Type 1 diabetes mellitus management and islet cell therapy: a new chapter in patient care.Cureus2023;15:e46912 PMCID:PMC10639080

[70] Bruemmer D.C-Peptide in insulin resistance and vascular complications: teaching an old dog new tricks.Circ Res2006;99:1149-51 PMCID:PMC1829170

[71] Walcher D,Poletek P.C-Peptide induces vascular smooth muscle cell proliferation: involvement of SRC-kinase, phosphatidylinositol 3-kinase, and extracellular signal-regulated kinase 1/2.Circ Res2006;99:1181-7

[72] Maddaloni E,Frier BM.C-peptide determination in the diagnosis of type of diabetes and its management: a clinical perspective.Diabetes Obes Metab2022;24:1912-26

[73] Otto-Buczkowska E.The clinical utility of C-peptide measurement in diabetology.Pediatr Endocrinol Diabetes Metab2015;20:63-8

[74] Mathieu C,Cerosaletti K.AG019-T1D-101 Trial InvestigatorsA first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab.Diabetologia2024;67:27-41 PMCID:PMC10709251

[75] Herold KC,Willi SM.Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.Diabetologia2013;56:391-400 PMCID:PMC3537871

[76] Perdigoto AL,Clark P.Immune Tolerance NetworkTreatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.Diabetologia2019;62:655-64

[77] Taylor PN,Lam A.Trial Outcome Markers Initiative collaborationC-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis.Lancet Diabetes Endocrinol2023;11:915-25

[78] Dwyer AJ,Fife BT.Antigen-specific T cell responses in autoimmune diabetes.Front Immunol2024;15:1440045 PMCID:PMC11358097

[79] Durinovic-Belló I.Autoimmune diabetes: the role of T cells, MHC molecules and autoantigens.Autoimmunity1998;27:159-77

[80] Xie Z,Zhou Z.Molecular mechanisms in autoimmune type 1 diabetes: a critical review.Clin Rev Allergy Immunol2014;47:174-92

[81] Khosravi-Maharlooei M,Borsotti C.Modeling human T1D-associated autoimmune processes.Mol Metab2022;56:101417 PMCID:PMC8739876

[82] Yue M,Min X.The role of islet autoantigen-specific T cells in the onset and treatment of type 1 diabetes mellitus.Front Immunol2024;15:1462384 PMCID:PMC11458421

[83] Russell WE,Herold KC.Response to comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005-1013.Diabetes Care2023;46:e210-1

[84] Blagov AV,Sukhorukov VN,Grechko AV.Type 1 diabetes mellitus: inflammation, mitophagy, and mitochondrial function.Mitochondrion2023;72:11-21

[85] Basaran E.Waist-to-height ratio as a novel marker of metabolic syndrome in patients with type 2 diabetes mellitus.Explor Endocr Metab Dis2025;2:101421

[86] Kosekli MA.The systemic immune inflammation index is a reliable and novel risk factor for metabolic dysfunction-associated fatty liver disease.Curr Med Res Opin2025;41:247-51

[87] Czajkowska JB,Zito S.Development of low blood glucose readings in nine non-diabetic patients treated with tumor necrosis factor-alpha inhibitors: a case series.J Med Case Rep2012;6:5 PMCID:PMC3266185

[88] Thakkar S,Nagendra L,Bhattacharya S.Teplizumab in type 1 diabetes mellitus: an updated review.touchREV Endocrinol2023;19:22-30 PMCID:PMC10769466

[89] Herold KC,Gottlieb PA,Raymond R.Teplizumab: a disease-modifying therapy for type 1 diabetes that preserves β-cell function.Diabetes Care2023;46:1848-56 PMCID:PMC10545553

[90] Orban T,Becker DJ.Type 1 Diabetes TrialNet Abatacept Study GroupCo-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.Lancet2011;378:412-9

[91] Jasim SA,Abdelbasset WK.Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases.Stem Cell Res Ther2022;13:101 PMCID:PMC8900359

[92] Loretelli C,Seelam AJ,Fiorina P.Cell therapy for type 1 diabetes.Expert Opin Biol Ther2020;20:887-97

[93] Wang Z,Mo L.The application potential of the regulation of tregs function by irisin in the prevention and treatment of immune-related diseases.Drug Des Devel Ther2024;18:3005-23

[94] Bellan M,Mele C.Pathophysiological role and therapeutic implications of vitamin d in autoimmunity: focus on chronic autoimmune diseases.Nutrients2020;12:789 PMCID:PMC7146294

[95] Yan X,Liu B.Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial.Signal Transduct Target Ther2023;8:158 PMCID:PMC10115841

[96] Wang G,Ma H.Phenolipid JE improves metabolic profile and inhibits gluconeogenesis via modulating AKT-mediated insulin signaling in STZ-induced diabetic mice.Pharmacol Res2023;187:106569

[97] Quarta A,Tripodi R,Chiarelli F.Diet and glycemic index in children with type 1 diabetes.Nutrients2023;15:3507 PMCID:PMC10459060

[98] Choudhary P.Hypoglycaemia in type 1 diabetes: technological treatments, their limitations and the place of psychology.Diabetologia2018;61:761-9 PMCID:PMC6448988